Version history

{
  "session_id": "sess_SDA-2026-04-13-gap-debate-20260412-094556-86f36bb3_20260414-011511",
  "round_number": 2,
  "agent_persona": "persona-skeptic",
  "agent_backend": "minimax/MiniMax-M2.7",
  "action": "critique",
  "content": "\n\n# Skeptic's Critique: K280 Acetylation Structural Hypotheses\n\n---\n\n## Hypothesis 1: Hydrophobic Core Destabilization via Salt Bridge Disruption\n\n### Strongest Weakness: The salt bridge network is not the primary stabilization source in this region.\n\nThe PHF6* motif (VQIINK) is not a folded hairpin stabilized primarily by K280–E283 contacts. Crystallographic and solution NMR studies of tau fragments show this region is intrinsically disordered in isolation (Mukhopadhyay et al., Protein Sci 2007; PMID: 17242429). The K280–E283 salt bridge, where it exists, is likely transient and context-dependent, forming only in rare conformational states. If the region is already dynamic, charge neutralization by acetylation cannot expose a cryptic β-strand edge that wasn't substantially buried to begin with.\n\n### Counter-Evidence and Complications\n\n**1.** The acetyl-mimic K280Q is a chemically imperfect surrogate. Glutamine is isosteric to glutamate, not to acetyl-lysine. K280Q retains a hydrogen bond donor (the amide NH) where acetyl-K280 has a carbonyl oxygen with different electronics and a methyl group creating steric bulk. The NMR chemical shift perturbations in Cohen et al. (J Biol Chem 2013; PMID: 23530048) may reflect local electrostatic changes from the Q mutation *per se*, not a conformational consequence of acetylation.\n\n**2.** The proposed FRET assay is confounded by labeling chemistry. The donor-acceptor pair requires free amines at K273 and K285. Acetylation at K280 *does not directly modify these positions*—but if the acetyltransferase preferentially modifies K280 when the protein is in a particular conformational state, that state may also affect solvent accessibility of K273 and K285. You cannot easily deconvolve fluorophore labeling efficiency from true FRET changes. A negative result could reflect failed labeling of one arm, not a conformational failure.\n\n**3.** Acetylation may not be sufficient alone. A substantial body of literature shows K280 acetylation alone does not drive aggregation in the absence of polyanionic cofactors (heparin, RNA, or fatty acids). If your mechanism requires acetylation to \"expose\" a nucleation surface, what prevents that surface from being immediately capped by molecular chaperones *in vivo*?\n\n### Pointed Question\n\n> You state acetylation unmasks backbone amides of V276/I277 as a β-strand nucleation edge. But the PHF6* motif is already aggregation-competent in unmodified tau—acetylation is not required for tau to form β-structure (witness the aggregation of unmodified PHF6* peptides in vitro). If the motif is already templating-competent without acetylation, what specific conformational change does acetylation *add* that explains its proposed role in disease onset?\n\n### Confidence Rating: **Weak**\n\nThe mechanism lacks a clear structural",
  "tokens_used": "705"
}